Balancing Between Ischemic and Bleeding Risk in PCI Patients With ‘Bi-Risk’
Author:
Open Access
- 1 January 2022
- journal article
- editorial
- Published by XMLink in Korean Circulation Journal
- Vol. 52 (4) , 338-340
Abstract
Korean Circulation Journal 대한심장학회지 순환기 Park MW. Korean Circ J. 2022 Feb;52:e35. https://doi.org/10.4070/kcj.2021.0429This publication has 9 references indexed in Scilit:
- Ticagrelor Monotherapy After 3-Month Dual Antiplatelet Therapy in Acute Coronary Syndrome by High Bleeding Risk: The Subanalysis From the TICO TrialKorean Circulation Journal, 2022
- Dual Antiplatelet Therapy after PCI in Patients at High Bleeding RiskNew England Journal of Medicine, 2021
- Ticagrelor monotherapy in patients at high bleeding risk undergoing percutaneous coronary intervention: TWILIGHT-HBREuropean Heart Journal, 2021
- Effect of Ticagrelor Monotherapy vs Ticagrelor With Aspirin on Major Bleeding and Cardiovascular Events in Patients With Acute Coronary SyndromeJAMA, 2020
- Validation of the Academic Research Consortium High Bleeding Risk Definition in Contemporary PCI PatientsJACC, 2020
- 2020 Korean Society of Myocardial Infarction Expert Consensus Document on Pharmacotherapy for Acute Myocardial InfarctionKorean Circulation Journal, 2020
- Drug-eluting or bare-metal stents for percutaneous coronary intervention: a systematic review and individual patient data meta-analysis of randomised clinical trialsThe Lancet, 2019
- Trade-off of myocardial infarction vs. bleeding types on mortality after acute coronary syndrome: lessons from the Thrombin Receptor Antagonist for Clinical Event Reduction in Acute Coronary Syndrome (TRACER) randomized trialEuropean Heart Journal, 2016
- Associations of major bleeding and myocardial infarction with the incidence and timing of mortality in patients presenting with non-ST-elevation acute coronary syndromes: a risk model from the ACUITY trialEuropean Heart Journal, 2009